期刊
EUROPEAN JOURNAL OF ENDOCRINOLOGY
卷 167, 期 3, 页码 343-351出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/EJE-12-0070
关键词
-
资金
- Pfizer, Inc.
- Novartis
- Ipsen
- Eli Lilly
- Warner Chilcott
- Tarsa
- Pfizer
- Novo-Nordisk
- Serono
Objective: Childhood-onset GH deficiency (COGHD) is associated with low bone mineral density (BMD). Adults with persistent COGHD may be at risk for insufficient bone accrual or bone loss during adulthood. The purpose of this study was to identify BMD predictors and to characterize the effects of GH replacement on BMD in COGHD adults with persistent GHD. Design: Retrospective analysis of the KIMS database. Methods: Variables predicting standardized BMD (sBMD) were identified. The effect of GH replacement (3 years) on BMD was examined. Results: Three hundred and fourteen COGHD adults (148 women, 166 men; 62 non-naive, 178 semi-naive, and 74 true naive, depending on length and timing of previous GH replacement), who had BMD measured in lumbar spine (LS) and femoral neck (FN) at study entry. In semi-naive subjects, a longer gap in GH replacement between childhood and adulthood was predictive of lower sBMD in the FN (r=-0.18, P=0.038). TSH deficiency predicted lower sBMD in the LS (r=-0.16, P=0.052). In true naive patients, a longer gap between onset of pituitary disease and study entry (r=-0.35, P=0.012), and female gender (r=-0.27, P=0.043) independently predicted lower sBMD in the FN. There were no differences in BMD increases between non-naive, semi-naive, and true naive subjects on GH replacement. Conclusions: In semi-naive subjects a longer interval off GH replacement was associated with lower sBMD in the FN. Among true naive patients, a longer gap between the onset of pituitary disease and GH replacement, and female gender predicted lower sBMD in the FN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据